Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report details a specific share repurchase transaction executed on August 25, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,327.5 pence per share; lowest price paid was 1,283.5 pence per share.
- Treasury Holdings (Settled): 502,996,816 shares (9.01% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,996,816 shares (9.92% of total voting rights).
- Shares in Issue: 5,079,783,904 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.92% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the execution of the authorized share buyback program. The Company intends to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,079,783,904) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.92% including unsettled shares).
- Review the price paid per share (1,283.5 to 1,327.5 pence) against market prices on August 25, 2011.
- Check subsequent filings for the settlement status of the 1,000,000 shares purchased.